169 related articles for article (PubMed ID: 29714569)
1. Anticancer Drug Prescription Patterns in Japan: Future Directions in Cancer Therapy.
Shibata S; Matsushita M; Saito Y; Suzuki T
Ther Innov Regul Sci; 2018 Nov; 52(6):718-723. PubMed ID: 29714569
[TBL] [Abstract][Full Text] [Related]
2. Optimal Anti-cancer Drug Profiles for Effective Penetration of the Anti-cancer Drug Market by Generic Drugs in Japan.
Shibata S; Matsushita M; Saito Y; Suzuki T
Ther Innov Regul Sci; 2018 Jul; 52(4):442-448. PubMed ID: 29714554
[TBL] [Abstract][Full Text] [Related]
3. Trends in prescription drug expenditures by Medicaid enrollees.
Banthin JS; Miller GE
Med Care; 2006 May; 44(5 Suppl):I27-35. PubMed ID: 16625061
[TBL] [Abstract][Full Text] [Related]
4. Prescription drugs: issues of cost, coverage, and quality.
Copeland C
EBRI Issue Brief; 1999 Apr; (208):1-21. PubMed ID: 10539445
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal trends in use of targeted therapies for treatment of malignant neoplasms of the eye: a population-based study in Taiwan.
Hsu JC; Gonzalez-Gonzalez LA; Lu VH; Lu CY
BMJ Open; 2016 May; 6(5):e010706. PubMed ID: 27235298
[TBL] [Abstract][Full Text] [Related]
6. Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan.
Satoh E; Sasaki Y; Ohkuma R; Takahashi T; Kubota Y; Ishida H; Hamada K; Kiuchi Y; Tsunoda T
Cancer Sci; 2018 Dec; 109(12):3896-3901. PubMed ID: 30315613
[TBL] [Abstract][Full Text] [Related]
7. Outpatient cancer drug costs: changes, drivers, and the future.
Halbert RJ; Zaher C; Wade S; Malin J; Lawless GD; Dubois RW
Cancer; 2002 Feb; 94(4):1142-50. PubMed ID: 11920485
[TBL] [Abstract][Full Text] [Related]
8. Rising cost of anticancer drugs in Australia.
Karikios DJ; Schofield D; Salkeld G; Mann KP; Trotman J; Stockler MR
Intern Med J; 2014 May; 44(5):458-63. PubMed ID: 24612257
[TBL] [Abstract][Full Text] [Related]
9. Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan.
Kawabata-Shoda E; Masuda S; Kimura H
J Clin Pharm Ther; 2012 Oct; 37(5):547-52. PubMed ID: 22428857
[TBL] [Abstract][Full Text] [Related]
10. [Future directions of anticancer drug development in Japan].
Akaza H; Kawai K; Tsuruo T; Tsukagoshi S; Aiba K; Shimada Y; Kakeji Y; Ishikawa H; Ikeda T; Nakamura S; Tamura T; Yamamoto N; Isonishi S; Hinotsu S; Hirose M; Katsura J
Gan To Kagaku Ryoho; 2008 Feb; 35(2):351-60. PubMed ID: 18281781
[TBL] [Abstract][Full Text] [Related]
11. Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients.
Tseng CW; Brook RH; Keeler E; Mangione CM
JAMA; 2003 Jul; 290(2):222-7. PubMed ID: 12851277
[TBL] [Abstract][Full Text] [Related]
12. Drug sales confirm clinical advantage of multi-target inhibition of drug escapes by anticancer kinase inhibitors.
Chen S; Yang SY; Chen Z; Tan Y; Jiang YY; Chen YZ
Drug Dev Res; 2019 Mar; 80(2):246-252. PubMed ID: 30422335
[TBL] [Abstract][Full Text] [Related]
13. Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011.
Shih YC; Smieliauskas F; Geynisman DM; Kelly RJ; Smith TJ
J Clin Oncol; 2015 Jul; 33(19):2190-6. PubMed ID: 25987701
[TBL] [Abstract][Full Text] [Related]
14. [Rising costs of drugs in hospitals in the period 1996-2000 and over the next few years].
Breekveldt-Postma NS; Zwart-van Rijkom JE; Egberts AC; Leufkens HG; Herings RM
Ned Tijdschr Geneeskd; 2002 Dec; 146(52):2547-51. PubMed ID: 12532669
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal trends in use and costs of targeted therapies for common cancers in Taiwan: a retrospective observational study.
Hsu JC; Lu CY
BMJ Open; 2016 Jun; 6(6):e011322. PubMed ID: 27266775
[TBL] [Abstract][Full Text] [Related]
16. Factors contributing to trends in prescription drug expenditures.
Suh DC; Lacy CR; Barone JA; Moylan D; Kostis JB
Clin Ther; 1999 Jul; 21(7):1241-53. PubMed ID: 10463521
[TBL] [Abstract][Full Text] [Related]
17. Why did drug spending increase during the 1990s? A decomposition based on Swedish data.
Gerdtham UG; Lundin D
Pharmacoeconomics; 2004; 22(1):29-42. PubMed ID: 14720080
[TBL] [Abstract][Full Text] [Related]
18. The demand for prescription drugs as a function of cost-sharing.
Leibowitz A; Manning WG; Newhouse JP
Soc Sci Med; 1985; 21(10):1063-9. PubMed ID: 3936186
[TBL] [Abstract][Full Text] [Related]
19. Price indexes for pharmaceuticals used by the elderly.
Thomas J; Schondelmeyer S
Health Care Financ Rev; 1992; 14(1):91-105. PubMed ID: 10124442
[TBL] [Abstract][Full Text] [Related]
20. Drug cost increases are generated by the 50 top selling pharmaceuticals.
Health Care Strateg Manage; 2001 Jun; 19(6):14-5, 1. PubMed ID: 11409091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
